Should you buy STERIS plc (Ireland) (STE)?
Updated
STERIS has earned a perfect Piotroski F-Score of 9/9 and analysts carry a consensus target implying 25% upside, but the stock is in a confirmed downtrend with both price and volume distribution pointing lower, and an elevated put-to-call ratio of 4.62 reflects significant bearish positioning by options market participants.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
STERIS earns a perfect Piotroski F-Score of 9/9 across all profitability, leverage, and operating efficiency criteria, indicating that the underlying business quality remains intact despite the price decline. Quality breakdown | STERIS maintains a Piotroski F-Score of at least 8/9 for the next 4 consecutive quarters, confirming that business fundamentals are not deteriorating alongside the price trend. | →Stable |
| CounterThe Piotroski score is backward-looking; the confirmed downtrend and C-suite departure flag suggest that the operating environment may be changing in ways the historical score does not yet capture. | ||
The analyst consensus price target of approximately $223 implies 25% upside from the current price of $205.93, suggesting that sell-side analysts view the current discount as a buying opportunity. Sentiment breakdown | The stock reaches $220, more than 7% above current price, within 12 months as the downtrend reverses and the valuation discount to consensus narrows. | →Stable |
| CounterAnalyst price targets often lag price action during sustained downtrends; the death cross pattern and MACD in confirmed negative territory suggest the consensus target may be revised down before price recovers. | ||
The put-to-call ratio of 4.62 indicates that options market participants are positioned approximately 4.6 times more bearish than bullish, signaling elevated concern about near-term downside. Key risks | Put-to-call ratio falls below 2.0 within 6 months as the downtrend resolves and bearish hedges expire or are closed, indicating sentiment normalization. | →Stable |
| CounterElevated put-to-call ratios in healthcare equipment companies can reflect legitimate fundamental hedging by institutional holders rather than speculative bearishness, and may persist through the entire downtrend. | ||
STERIS earns a perfect Piotroski F-Score of 9/9 across all profitability, leverage, and operating efficiency criteria, indicating that the underlying business quality remains intact despite the price decline.
→Stable- Expectation
- STERIS maintains a Piotroski F-Score of at least 8/9 for the next 4 consecutive quarters, confirming that business fundamentals are not deteriorating alongside the price trend.
CounterThe Piotroski score is backward-looking; the confirmed downtrend and C-suite departure flag suggest that the operating environment may be changing in ways the historical score does not yet capture.
The analyst consensus price target of approximately $223 implies 25% upside from the current price of $205.93, suggesting that sell-side analysts view the current discount as a buying opportunity.
→Stable- Expectation
- The stock reaches $220, more than 7% above current price, within 12 months as the downtrend reverses and the valuation discount to consensus narrows.
CounterAnalyst price targets often lag price action during sustained downtrends; the death cross pattern and MACD in confirmed negative territory suggest the consensus target may be revised down before price recovers.
The put-to-call ratio of 4.62 indicates that options market participants are positioned approximately 4.6 times more bearish than bullish, signaling elevated concern about near-term downside.
→Stable- Expectation
- Put-to-call ratio falls below 2.0 within 6 months as the downtrend resolves and bearish hedges expire or are closed, indicating sentiment normalization.
CounterElevated put-to-call ratios in healthcare equipment companies can reflect legitimate fundamental hedging by institutional holders rather than speculative bearishness, and may persist through the entire downtrend.
▸ Show 1 more pillar▾ Show fewer
STERIS depends on third-party suppliers of ethylene oxide and cobalt-60 for its sterilization services, creating a supply chain concentration risk that could disrupt revenue if either input becomes unavailable or significantly more expensive.
→Stable- Expectation
- No major supply disruption to ethylene oxide or cobalt-60 occurs over the next 12 months, and management reports no material change to supply chain costs in quarterly commentary.
CounterRegulatory pressure on ethylene oxide use in medical device sterilization has been increasing; an adverse EPA ruling or supplier capacity constraint could force STERIS to absorb significant costs or lose contracts.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1STERIS earns a perfect Piotroski F-Score of 9/9 across all profitability, leverage, and operating efficiency criteria, indicating that the underlying business quality remains intact despite the price decline.
Trip ifPiotroski F-Score falls below 7/9 in any reported quarter over the next 12 months, signaling fundamental deterioration below the quality threshold.
- P2The analyst consensus price target of approximately $223 implies 25% upside from the current price of $205.93, suggesting that sell-side analysts view the current discount as a buying opportunity.
Trip ifAnalyst consensus price target falls below $200, less than 3% below the current price of $205.93, signaling broad analyst downgrades are materializing.
- P3The put-to-call ratio of 4.62 indicates that options market participants are positioned approximately 4.6 times more bearish than bullish, signaling elevated concern about near-term downside.
Trip ifPut-to-call ratio rises above 6.0, more than 30% higher than the current 4.62, indicating bearish positioning is intensifying rather than unwinding.
- P4STERIS depends on third-party suppliers of ethylene oxide and cobalt-60 for its sterilization services, creating a supply chain concentration risk that could disrupt revenue if either input becomes unavailable or significantly more expensive.
Trip ifStock price drops below $190, more than 8% below the current $205.93, following a supply disruption disclosure or regulatory adverse action announcement.
How the engine reached this verdict
TrendMatrix's engine output for STERIS plc (Ireland) (STE) is HOLD_IF_HOLDING with medium conviction, score 5.9/10 at $210.97. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
On the bull side: Strong growth profile. On the bear side: Concentration risk — Supplier: ethylene oxide and cobalt-60; Thin upside margin: 6.2%; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend). Active engine warnings: V9 Gate Failed: ASYMMETRY:1.1<1.5@spot.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $201.34 for existing positions. Asymmetric R:R is 1.44, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
HOLD flips toward BUY_WAIT if reward-to-risk at 1.1 vs threshold 1.5 clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates STE — 10-dimension breakdown →
Bull case
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Supplier: ethylene oxide and cobalt-60
- ▸Thin upside margin: 6.2%
- ▸Below 200-MA, MA slope -1.8%/30d (confirmed downtrend)